Developer docs
API playgroundTry for free, no card

Search company profiles

SGD Pharma

Full company profile

uuid0004mml

Namestring
SGD Pharma
Legal namestring
SGD S.A.
Websiteurl
sgd-pharma.com
Company typeenum
Private
Founded yearint
1917
Descriptiontext

SGD Pharma is a global manufacturer of glass primary packaging for the pharmaceutical industry, producing Type I, II and III borosilicate and soda-lime vials, ampoules, infusion bottles, syringes, droppers and nasal bottles in both molded and tubular formats. The company operates 10 ISO 15378-certified manufacturing plants across France, Germany, India, China and Italy, with daily output exceeding 8 million units (more than 2 billion vials annually), and supports customers with proprietary value-added treatments including SEALIAN internal siliconization, Sterinity ready-to-use sterile vials, Velocity Vials (with Corning), IDENCY next-generation vials, EasyLyo lyophilization vials, Clareo Type II vials, U-Save nasal bottles, and PROSEAL+ thermoseal pre-treatment. Its commercial model is a direct enterprise sales motion through 9 sales offices and a channel network of approximately 90 distributors and partners, supported by on-site customer audits, regulatory affairs support and a laboratory testing service; pricing is quote-based under multi-year contracts with pharmaceutical manufacturers.

The business serves injectable/parenteral, infusion, oral medication, nasal delivery, beauty and consumer healthcare segments. SGD Pharma is privately held under PAI Partners as lead sponsor with China Jianyin Investment (JIC) as a significant minority shareholder following a separation from the legacy SGD Group perfumery entity; the company has accelerated capacity and capability expansion since 2017, including the Saint-Quentin-la-Motte molded glass center of excellence (€65M+), the Zhanjiang furnace rebuild (+11% capacity), the Cogent Glass tubular conversion platform in India, the 2023 Corning joint venture for a Telangana glass tubing facility, and the Q4 2025 acquisition of Alphial for additional Italian tubular capacity. Environmentally, the company is positioned in the top 1% of EcoVadis-rated firms globally (Platinum, 90/100 in 2025), carries CDP Climate A, and has SBTi-validated targets to reduce emissions 42% by 2030 and 65% by 2040 versus 2022.

Short descriptiontext

SGD Pharma is a global manufacturer of pharmaceutical glass primary packaging — Type I, II and III vials, ampoules, infusion bottles, nasal bottles and droppers — operating 10 ISO 15378-certified plants in Europe and Asia and serving injectable, infusion, oral and nasal drug producers worldwide through direct sales and an extensive distributor network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical glass packaging, glass vials manufacturing, injectable packaging solutions, pharmaceutical primary packaging, glass ampoules production
Industry3 codes
PRIMARYIMALAEAB
Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes)
SECONDARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)
NAICS code2 codes
  • Glass Container Manufacturing327213
  • Glass and Glass Product Manufacturing32721
SIC code2 codes
  • Glass Containers3221
  • Glass & Glassware, Pressed Or Blown3220
Product category
Pharmaceutical Glass Packaging
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Glass Packaging Sales
TypeHardware Sales
Description

Manufacturing and selling pharmaceutical glass primary packaging including vials, bottles, ampoules in Type I, II, and III glass for injectable, infusion, and oral drug delivery applications. Revenue generated from direct sales to pharmaceutical manufacturers worldwide.

sgd-pharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D
Pricing details1 tier
1Custom quotation-based pricing for pharmaceutical glass packaging
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed - B2B manufacturer requiring custom quotes based on volume, specifications, and contract terms

sgd-pharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Embelia
Description

Full service primary packaging for beauty and health sectors (formerly VG Emballage)

sgd-pharma.com
Core offering1 text field

SGD Pharma manufactures glass primary packaging for the pharmaceutical industry, producing Type I, II, and III borosilicate and soda-lime glass vials, bottles, ampoules, dropper bottles, aerosols, and specialty containers. The company serves injectable, infusion, oral, nasal, beauty, and healthcare applications with value-added treatments such as internal siliconization, plastic coating, and sterile ready-to-use formats.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • EcoVadis score of 90/100 earning Platinum medal for second consecutive year - top 1% globally
+3 more records
Product overview1 text field

SGD Pharma is a global leader in glass pharmaceutical primary packaging, offering a comprehensive portfolio of products and services for the pharmaceutical, healthcare, and beauty industries. The company's core offerings include Type I, II, and III glass vials (both molded and tubular formats), ampoules, infusion bottles, and oral liquid containers. Key branded products include Sterinity (sterile RTU vials), Idency (next-generation vials), EasyLyo (lyophilization vials), Clareo (premium Type II vials), and Velocity Vials (with Corning technology). The company provides value-added services including SEALIAN internal siliconization, PROSEAL+ pre-treated glass for thermosealing, plastic coating, and LabServices. SGD Pharma operates 10 manufacturing plants across Europe and Asia, with recent expansion through the Alphial acquisition (Q4 2025) strengthening tubular glass capabilities. The company serves diverse markets including injectables, infusions, oral medications, nasal delivery, and beauty/personal care packaging.

Product and service6 records
1Injectable Vials Type I
CategoryPharmaceutical Glass Vials
Description

Type I borosilicate glass injectable vials available in both molded and tubular glass formats, designed for parenteral pharmaceutical applications requiring high chemical resistance.

2Sterinity
CategoryPharmaceutical Glass Vials
Description

High-quality depyrogenated sterile empty vials designed for aseptic filling in pharmaceutical manufacturing as part of the ready-to-use (RTU) vial portfolio.

3Idency
CategoryPharmaceutical Glass Vials
Description

Next-generation molded glass vials offering enhanced chemical durability and performance characteristics for injectable drug packaging.

4EasyLyo
CategoryPharmaceutical Glass Vials
Description

Vials specifically designed for lyophilization (freeze-drying) applications in pharmaceutical manufacturing.

5Clareo
CategoryPharmaceutical Glass Vials
Description

Premium Type II glass vials for injectable drug solutions. Shortlisted as finalist for CPhI Pharma Awards 2018 in the Packaging category.

6Velocity Vials
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-08-01
Description

SGD Pharma acquired Alphial from Entangled Capital and Capital Dynamics in Q4 2025, expanding tubular glass capabilities with Italian-based production sites, strengthening European footprint.

2Corning Incorporated
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2023-04-01
Description

Joint venture for glass tubing facility in Telangana, India. Combines Corning's Velocity Vial glass-coating technology with SGD Pharma's vial-converting expertise. Phase one for Velocity Vials production started March 2024, tubing production began late 2025. Co-locates tubing production and vial converting to improve product quality, filling-line productivity, and supply chain resilience.

pharmabiz.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with Ompi Ez-fill platform to offer sterile and depyrogenated vials to parenteral market. SGD Pharma became first molded glass supplier to offer RTU vials through Ompi platform.

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Bormioli Pharma is an Italian manufacturer of pharmaceutical glass and plastic packaging, including vials, bottles, and containers for injectables and oral medications. The company is a direct competitor to SGD Pharma in European pharmaceutical glass packaging markets, with similar product offerings in Type I, II, and III glass vials.

TypeDirect peer
Description

Schott Pharma is the leading global manufacturer of pharmaceutical glass packaging, including vials, ampoules, syringes, and cartridges made from Type I borosilicate glass. They are the most direct competitor to SGD Pharma, serving the same injectable, infusion, and parenteral pharmaceutical markets with comparable product portfolios and regulatory certifications.

3Nipro Corporation
TypeDirect peer
Description

Nipro Corporation is a Japanese manufacturer of pharmaceutical glass packaging, including vials, ampoules, syringes, and cartridges, with global production and sales capabilities. The company competes directly with SGD Pharma in pharmaceutical glass primary packaging, particularly in the Asian and European markets.

TypeDirect peer
Description

Gerresheimer is a European-based manufacturer of pharmaceutical packaging made from glass and plastic, including vials, ampoules, syringes, and containers for injectable drugs. The company competes directly with SGD Pharma across multiple product categories including pharmaceutical glass vials, with comparable global manufacturing footprint and customer base in pharma.

TypeRegional player
Description

Verallia is a European leader in glass packaging for beverages and food, with limited but growing presence in pharmaceutical glass. While primarily focused on food and beverage glass, Verallia competes with SGD Pharma in glass manufacturing capabilities and could expand into pharmaceutical-grade products, particularly in European markets.

TypeDirect peer
Description

Stevanato Group is a global provider of pharmaceutical containment solutions, including glass vials, syringes, and its EZ-fill ready-to-use platform. SGD Pharma has a partnership with Stevanato's Ompi EZ-fill platform but is also a direct competitor in molded and tubular glass vials for injectables, particularly as both companies expand in RTU sterile formats.

TypeBroad incumbent
Description

West Pharmaceutical Services is a global leader in injectable drug containment and delivery, including elastomer components, stoppers, seals, syringes, and integrated systems. While West's primary focus is elastomers and delivery systems rather than glass, they compete with SGD Pharma in the broader pharmaceutical primary packaging market, particularly for injectable drugs.

8Corning Incorporated (Pharma)
TypeEmerging player
Description

Corning is the primary supplier of pharmaceutical glass tubing and a strategic JV partner of SGD Pharma for Velocity Vials in India. While Corning provides tubing to multiple vial converters, its proprietary Velocity Vial coating technology and direct entry into converted vials via the SGD JV creates partial overlap with SGD Pharma's product portfolio in specific high-end injectable applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance16 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SGD Pharma

Pharmaceutical Glass Packagingsgd-pharma.com

SGD Pharma is a global manufacturer of pharmaceutical glass primary packaging — Type I, II and III vials, ampoules, infusion bottles, nasal bottles and droppers — operating 10 ISO 15378-certified plants in Europe and Asia and serving injectable, infusion, oral and nasal drug producers worldwide through direct sales and an extensive distributor network.

What SGD Pharma does

SGD Pharma is a global manufacturer of glass primary packaging for the pharmaceutical industry, producing Type I, II and III borosilicate and soda-lime vials, ampoules, infusion bottles, syringes, droppers and nasal bottles in both molded and tubular formats. The company operates 10 ISO 15378-certified manufacturing plants across France, Germany, India, China and Italy, with daily output exceeding 8 million units (more than 2 billion vials annually), and supports customers with proprietary value-added treatments including SEALIAN internal siliconization, Sterinity ready-to-use sterile vials, Velocity Vials (with Corning), IDENCY next-generation vials, EasyLyo lyophilization vials, Clareo Type II vials, U-Save nasal bottles, and PROSEAL+ thermoseal pre-treatment. Its commercial model is a direct enterprise sales motion through 9 sales offices and a channel network of approximately 90 distributors and partners, supported by on-site customer audits, regulatory affairs support and a laboratory testing service; pricing is quote-based under multi-year contracts with pharmaceutical manufacturers.

The business serves injectable/parenteral, infusion, oral medication, nasal delivery, beauty and consumer healthcare segments. SGD Pharma is privately held under PAI Partners as lead sponsor with China Jianyin Investment (JIC) as a significant minority shareholder following a separation from the legacy SGD Group perfumery entity; the company has accelerated capacity and capability expansion since 2017, including the Saint-Quentin-la-Motte molded glass center of excellence (€65M+), the Zhanjiang furnace rebuild (+11% capacity), the Cogent Glass tubular conversion platform in India, the 2023 Corning joint venture for a Telangana glass tubing facility, and the Q4 2025 acquisition of Alphial for additional Italian tubular capacity. Environmentally, the company is positioned in the top 1% of EcoVadis-rated firms globally (Platinum, 90/100 in 2025), carries CDP Climate A, and has SBTi-validated targets to reduce emissions 42% by 2030 and 65% by 2040 versus 2022.

SGD Pharma firmographics

Firmographics
Name
SGD Pharma
Legal name
SGD S.A.
Website
https://sgd-pharma.com
Company type
Private
Founded year
1917
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
SGD Pharma is a global manufacturer of pharmaceutical glass primary packaging — Type I, II and III vials, ampoules, infusion bottles, nasal bottles and droppers — operating 10 ISO 15378-certified plants in Europe and Asia and serving injectable, infusion, oral and nasal drug producers worldwide through direct sales and an extensive distributor network.
Ownership category
akta.pro rank

SGD Pharma industry classification

Industry
Product category
Pharmaceutical Glass Packaging
NAICS
Glass Container Manufacturing (327213), Glass and Glass Product Manufacturing (32721)
SIC
Glass Containers (3221), Glass & Glassware, Pressed Or Blown (3220)
akta.pro industry
PRIMARYIMALAEAB
Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes)
SECONDARYIMALAIAA
Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules)
SECONDARYIMALAIAE
Parenteral & Injectable Packaging Components (Stoppers, Seals, Syringes, Cartridges)

Keywords

  • Pharmaceutical glass packaging
  • Glass vials manufacturing
  • Injectable packaging solutions
  • Pharmaceutical primary packaging
  • Glass ampoules production

Where SGD Pharma is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices10 records

Markets served

SGD Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Infrastructure, Personnel, Technology or R&D

Revenue model

  1. Pharmaceutical Glass Packaging Sales: Manufacturing and selling pharmaceutical glass primary packaging including vials, bottles, ampoules in Type I, II, and III glass for injectable, infusion, and oral drug delivery applications. Revenue generated from direct sales to pharmaceutical manufacturers worldwide.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom quotation-based pricing for pharmaceutical glass packaging

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

SGD Pharma product offering

Product offering

Core offering

SGD Pharma manufactures glass primary packaging for the pharmaceutical industry, producing Type I, II, and III borosilicate and soda-lime glass vials, bottles, ampoules, dropper bottles, aerosols, and specialty containers. The company serves injectable, infusion, oral, nasal, beauty, and healthcare applications with value-added treatments such as internal siliconization, plastic coating, and sterile ready-to-use formats.

Product overview

SGD Pharma is a global leader in glass pharmaceutical primary packaging, offering a comprehensive portfolio of products and services for the pharmaceutical, healthcare, and beauty industries. The company's core offerings include Type I, II, and III glass vials (both molded and tubular formats), ampoules, infusion bottles, and oral liquid containers. Key branded products include Sterinity (sterile RTU vials), Idency (next-generation vials), EasyLyo (lyophilization vials), Clareo (premium Type II vials), and Velocity Vials (with Corning technology). The company provides value-added services including SEALIAN internal siliconization, PROSEAL+ pre-treated glass for thermosealing, plastic coating, and LabServices. SGD Pharma operates 10 manufacturing plants across Europe and Asia, with recent expansion through the Alphial acquisition (Q4 2025) strengthening tubular glass capabilities. The company serves diverse markets including injectables, infusions, oral medications, nasal delivery, and beauty/personal care packaging.

Differentiator

Problem solved

Functional benefit

Brands

  • Embelia: Full service primary packaging for beauty and health sectors (formerly VG Emballage)

Products and services

  • Injectable Vials Type I Type I borosilicate glass injectable vials available in both molded and tubular glass formats, designed for parenteral pharmaceutical applications requiring high chemical resistance.
  • Sterinity High-quality depyrogenated sterile empty vials designed for aseptic filling in pharmaceutical manufacturing as part of the ready-to-use (RTU) vial portfolio.
  • Idency Next-generation molded glass vials offering enhanced chemical durability and performance characteristics for injectable drug packaging.
  • EasyLyo Vials specifically designed for lyophilization (freeze-drying) applications in pharmaceutical manufacturing.
  • Clareo Premium Type II glass vials for injectable drug solutions. Shortlisted as finalist for CPhI Pharma Awards 2018 in the Packaging category.
  • Velocity Vials

Quantifiable outcome

  • EcoVadis score of 90/100 earning Platinum medal for second consecutive year - top 1% globally
  • +3 more outcomes

Companies that use SGD Pharma

Customer profile

Named customers2 records

Segments6 records

Ideal customer profiles3 records

SGD Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

SGD Pharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • AlphialcoreStrategic or Co-development Partner · 1 August 2025SGD Pharma acquired Alphial from Entangled Capital and Capital Dynamics in Q4 2025, expanding tubular glass capabilities with Italian-based production sites, strengthening European footprint.
  • Corning IncorporatedflagshipStrategic or Co-development Partner · 1 April 2023Joint venture for glass tubing facility in Telangana, India. Combines Corning's Velocity Vial glass-coating technology with SGD Pharma's vial-converting expertise. Phase one for Velocity Vials production started March 2024, tubing production began late 2025. Co-locates tubing production and vial converting to improve product quality, filling-line productivity, and supply chain resilience.
  • Ompi (Stevanato Group)coreStrategic or Co-development PartnerPartnership with Ompi Ez-fill platform to offer sterile and depyrogenated vials to parenteral market. SGD Pharma became first molded glass supplier to offer RTU vials through Ompi platform.

Scale indicators7 records

Recent moves11 records

Expansion highlights7 records

SGD Pharma competitors and assessment

Company assessment

Direct peers

  • Bormioli Pharma: Bormioli Pharma is an Italian manufacturer of pharmaceutical glass and plastic packaging, including vials, bottles, and containers for injectables and oral medications. The company is a direct competitor to SGD Pharma in European pharmaceutical glass packaging markets, with similar product offerings in Type I, II, and III glass vials.
  • Schott Pharma: Schott Pharma is the leading global manufacturer of pharmaceutical glass packaging, including vials, ampoules, syringes, and cartridges made from Type I borosilicate glass. They are the most direct competitor to SGD Pharma, serving the same injectable, infusion, and parenteral pharmaceutical markets with comparable product portfolios and regulatory certifications.
  • Nipro Corporation: Nipro Corporation is a Japanese manufacturer of pharmaceutical glass packaging, including vials, ampoules, syringes, and cartridges, with global production and sales capabilities. The company competes directly with SGD Pharma in pharmaceutical glass primary packaging, particularly in the Asian and European markets.
  • Gerresheimer AG: Gerresheimer is a European-based manufacturer of pharmaceutical packaging made from glass and plastic, including vials, ampoules, syringes, and containers for injectable drugs. The company competes directly with SGD Pharma across multiple product categories including pharmaceutical glass vials, with comparable global manufacturing footprint and customer base in pharma.
  • Stevanato Group: Stevanato Group is a global provider of pharmaceutical containment solutions, including glass vials, syringes, and its EZ-fill ready-to-use platform. SGD Pharma has a partnership with Stevanato's Ompi EZ-fill platform but is also a direct competitor in molded and tubular glass vials for injectables, particularly as both companies expand in RTU sterile formats.

Regional players

  • Verallia: Verallia is a European leader in glass packaging for beverages and food, with limited but growing presence in pharmaceutical glass. While primarily focused on food and beverage glass, Verallia competes with SGD Pharma in glass manufacturing capabilities and could expand into pharmaceutical-grade products, particularly in European markets.

Broad incumbents

  • West Pharmaceutical Services: West Pharmaceutical Services is a global leader in injectable drug containment and delivery, including elastomer components, stoppers, seals, syringes, and integrated systems. While West's primary focus is elastomers and delivery systems rather than glass, they compete with SGD Pharma in the broader pharmaceutical primary packaging market, particularly for injectable drugs.

Emerging players

  • Corning Incorporated (Pharma): Corning is the primary supplier of pharmaceutical glass tubing and a strategic JV partner of SGD Pharma for Velocity Vials in India. While Corning provides tubing to multiple vial converters, its proprietary Velocity Vial coating technology and direct entry into converted vials via the SGD JV creates partial overlap with SGD Pharma's product portfolio in specific high-end injectable applications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

SGD Pharma compliance and trust

Trust signal

Compliance16 records

SGD Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SGD Pharma leadership team

Management profile

Number of profiles

Profiles4 records

SGD Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

SGD Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SGD Pharma M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SGD Pharma

What does SGD Pharma do?

SGD Pharma manufactures glass primary packaging for the pharmaceutical industry, producing Type I, II, and III borosilicate and soda-lime glass vials, bottles, ampoules, dropper bottles, aerosols, and specialty containers. The company serves injectable, infusion, oral, nasal, beauty, and healthcare applications with value-added treatments such as internal siliconization, plastic coating, and sterile ready-to-use formats.

Is SGD Pharma a public or private company?

SGD Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was SGD Pharma founded?

SGD Pharma was founded in 1917. It employs 1,001 to 5,000 people.

Where is SGD Pharma based?

SGD Pharma is headquartered in Hyderabad, India, in the Asia region.

How does SGD Pharma make money?

One revenue line is on record: pharmaceutical Glass Packaging Sales.

Who are SGD Pharma's main competitors?

Direct peers on record are Bormioli Pharma, Schott Pharma, Nipro Corporation, Gerresheimer AG and Stevanato Group. Verallia is listed as a regional player. West Pharmaceutical Services is listed as a broad incumbent. Corning Incorporated (Pharma) is listed as an emerging player.

Does SGD Pharma have an API?

No public API is recorded for SGD Pharma.

What industry is SGD Pharma in?

SGD Pharma's product category is Pharmaceutical Glass Packaging. Its primary akta.pro industry code is IMALAEAB, Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes), with a secondary code of IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules). Its NAICS code is 327213 and its SIC code is 3221.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Packaging GatewaySGD Pharma expands moulded and tubular glass packaging portfolioSGD Pharma expanded its moulded and tubular glass packaging portfolio with new nasal and injectable vials, plus a third-party processing service. The containers are produced in ISO 5 environments and include a hydrophobic surface treatment to reduce residue. The company aims to offer a single-vendor solution for pre-treated tubular formats.Healthcare PackagingSGD Pharma Presents Pharma Packaging Innovation and Decarbonization From: SGD PharmaSGD Pharma showcased its pharmaceutical glass packaging portfolio including SEALIAN, IDENCY, and Sterinity EZ-fill solutions designed to enhance drug integrity and operational efficiency. Following the acquisition of Alphial in Q4 2025, the company expanded its tubular glass capabilities with Italian-based production sites, strengthening its European footprint. SGD Pharma retained EcoVadis Platinum status with a score of 90 and is pursuing SBTi-validated targets to reduce carbon emissions by 42% by 2030 and 65% by 2040 compared to 2022 levels.Grand View ResearchPharmaceutical Glass Packaging Market To Reach $51.56Bn By 2033The global pharmaceutical glass packaging market is projected to reach $51.56 billion by 2033, growing at a 10.5% CAGR from 2026 to 2033. Growth is driven by glass's recyclability and chemical inertness, while challenges include high costs and plastic alternatives. Key players include Corning, Nipro, and SGD Pharma.Cosmetics BusinessSGD and Aptar win 2015 Luxe Pack in Green awardsAt Luxe Pack Monaco 2015, SGD won Best Green Packaging Solution for Verre Néo Infini, a transparent glass made from 90% recycled materials. Aptar Beauty + Home won Best Corporate Social Responsibility Approach for recycling 90% of its industrial waste. The awards highlighted sustainability combined with aesthetics in luxury packaging.India's most comprehensive portal on pharmaceutical NewsCorning and SGD Pharma open glass tubing facility in Telangana to expand pharmaceutical packagingCorning Incorporated and SGD Pharma have opened a new glass tubing facility in Telangana, India, to manufacture high-quality Type I borosilicate glass tubing used for injectable drug packaging and biologics. The facility combines Corning's proprietary Velocity Vial glass-coating technology with SGD Pharma's vial-converting expertise, co-locating tubing production and vial converting to improve product quality, filling-line productivity, and supply chain resilience. The joint venture was incorporated in April 2023 with phase one for Velocity Vials production starting in March 2024 and tubing production beginning in late 2025.ContractpharmaSGD Pharma to Acquire Alphial S.r.l.SGD Pharma agreed to acquire Alphial S.r.l., an Italian producer of tubular vials and ampoules. The deal will expand SGD Pharma's European market presence and is subject to Italian FDI clearance. Integration will begin after closing.SgtSociety of Glass TechnologySGD Pharma has announced an agreement with Italian Private Equity firm Entangled Capital to acquire Alphial, a tubular glass converting company that manufactures ampoules, vials and Ready To Use products. Alphial employs more than 220 people across four manufacturing sites in Italy. The acquisition is intended to enhance SGD Pharma's capabilities and expand its tubular glass manufacturing presence in Europe.Market Report Analyticspharmaceuticals glass bottles Market Strategies for the Next Decade: 2025-2033A market research report projects the global pharmaceuticals glass bottles market will reach approximately $8 billion in 2025, growing at a compound annual growth rate of 5% through 2033. The expansion is primarily driven by increasing demand for injectable drugs and biologics, alongside technological advancements in manufacturing and sustainability initiatives. Key industry players such as Gerresheimer, Schott, SGD Pharma, and West Pharma are actively shaping the competitive landscape through strategic investments, product innovations, and capacity expansions.Global Growth InsightsGlass Bottles Market Insights & Global Trends 2033The global glass bottles market is projected to grow from USD 42,920.1 million in 2024 to USD 69,195.84 million by 2033, driven by demand for sustainable packaging and strong performance in the beverage and pharmaceutical sectors. Key players including SGD Pharma and AGI Glaspac are leading innovations such as lightweight and eco-friendly designs to address cost and sustainability challenges. The Asia-Pacific region is emerging as a significant growth area due to urbanization and rising disposable incomes.PharmiWeb.comSGD Pharma advances sustainable manufacturing and supply chain innovation at DCAT Week 2025 in New YorkSGD Pharma will attend DCAT Week 2025 in New York to showcase its sustainable manufacturing and supply chain innovations. The company has invested millions to modernize glass production, and its EcoVadis platinum medal and SBTi-validated decarbonization targets were highlighted. It will also present new siliconization and vial offerings to address pharma industry needs.